English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

The measurement of effort and performance validity is essential for computerized testing where less direct supervision is needed. The clinical validation of an Automated Neuropsychological Metrics-Performance Validity Index (ANAM-PVI) was examined by converting ANAM test scores into a common metric based on their relative infrequency in an outpatient clinic sample with presumed good effort. Optimal ANAM-PVI cut-points were determined using receiver operator characteristic (ROC) curve analyses and an a priori specificity of 90%. Sensitivity/specificity was examined in available validation samples (controls, simulators, and neurorehabilitation patients). ANAM-PVI scores differed between groups with simulators scoring the highest. ROC curve analysis indicated excellent discriminability of ANAM-PVI scores ≥5 to detect simulators versus controls (area under the curve = 0.858; odds ratio for detecting suboptimal performance = 15.6), but resulted in a 27% false-positive rate in the clinical sample. When specificity in the clinical sample was set at 90%, sensitivity decreased (68%), but was consistent with other embedded effort measures. Results support the ANAM-PVI as an embedded effort measure and demonstrate the value of sample-specific cut-points in groups with cognitive impairment. Examination of different cut-points indicates that clinicians should choose sample-specific cut-points based on sensitivity and specificity rates that are most appropriate for their patient population with higher cut-points for those expected to have severe cognitive impairment (e.g., dementia or severe acquired brain injury).

Initial Clinical Validation of an Embedded Performance Validity Measure within the Automated Neuropsychological Metrics (ANAM)